Legal Representation
Attorney
Colleen Ganin
USPTO Deadlines
Next Deadline
1931 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-11-12)
Due Date
November 12, 2030
Grace Period Ends
May 12, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
36 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 28, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 28, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 28, 2025 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Feb 28, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Nov 12, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 12, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 10, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Oct 10, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Oct 9, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 9, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 9, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Oct 9, 2024 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Aug 5, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 5, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Aug 5, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Aug 5, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Feb 7, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 5, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 5, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 5, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 8, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 13, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 13, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 24, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 9, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 9, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| May 9, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 9, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 9, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Mar 1, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 1, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 1, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 4, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 30, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Aug 27, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 9, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 035
Promoting public awareness about cancer; promoting public awareness about chimeric antigen receptor T cell therapy; promoting public awareness about research, detection, diagnosis, and medical treatments in the fields of pharmaceuticals, cell therapies, chimeric antigen receptor T cell therapy, oncology, and cancer
First Use Anywhere:
Oct 11, 2022
First Use in Commerce:
Oct 11, 2022
Class 042
Providing information about medical research in the field of cancer; providing information about medical research in the field of chimeric antigen receptor T cell therapy; medical and scientific research in the field of cancer treatment and chimeric antigen receptor T cell therapy
First Use Anywhere:
Oct 11, 2022
First Use in Commerce:
Oct 11, 2022
Class 044
Providing medical information in the field of cancer; providing medical information in the field of chimeric antigen receptor T cell therapy; providing medical information about research, detection, diagnosis, and medical treatments in the fields of cancer, immunotherapy, pharmaceuticals, oncology, cell therapies, and chimeric antigen receptor T cell therapy via a website
First Use Anywhere:
Oct 11, 2022
First Use in Commerce:
Oct 11, 2022
Additional Information
Design Mark
The mark consists of a half-circle made of polka dots to the left of the words "CAR TOGETHER" with overlapping "T"s above the words "MAKING ALLOGENEIC CAR T A REALITY FOR PATIENTS"".
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
035
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"ALLOGENEIC CAR T"